CDH2 and cancer: Transcriptional “switch” from E-Cadherin to N-cadherin expression in cancer cells results in acquisition of a mesenchymal phenotype characterized by loss of cell–cell junctions and acquisition of elongated shape, increased motility and invasive capacity [44, 46].